COMP <GO>
INFU vs JNJ // RSI-14 & 200D SMA MOMENTUM
InfuSystems Holdings Inc. (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: INFU 3
— JNJ 9
▲ RSI-14 & 200D SMA MOMENTUM LEADER: JNJ
LAST: $14.45 (+0.91%) • MKT CAP: $287.8M
rsi-technicals
58.6
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
rsi-technicals
62.1
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INFU VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INFU | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 56.00% | 67.90% | -11.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 12.80% | 25.50% | -12.70 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 24.5x | 18.5x | +6.00 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 8.29% | 2.97% | +5.32 | INFU | /fcf-yield <GO> |
| Operating Margin | 8.30% | 34.70% | -26.40 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 4.60% | 28.50% | -23.90 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 6.40% | 6.00% | +0.40 | INFU | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.16 | 5.59 | -0.43 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | INFU | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 58.6 | 62.1 | -3.52 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 40.4x | 23.0x | +17.40 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $287.8M | $662.49B | -$662.20B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INFU REV | JNJ REV | INFU GROSS % | JNJ GROSS % | INFU FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $143.4M | $94.19B | 56.0% | 67.9% | $23.8M | $19.70B |
| FY 2024 | $134.9M | $88.82B | 52.2% | 69.1% | $19.4M | $19.84B |
| FY 2023 | $125.8M | $85.16B | — | — | $11.2M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INFU // BETA —
JNJ // BETA 1.08